Newsroom

⁹⁹ᵐTc-maraciclatide Granted FDA Fast Track Designation for the Visualization of Inflammation in Interstitial Lung Disease 

Serac Healthcare Limited announced today that the US Food and Drug Administration (FDA) has granted Fast Track Designation to ^99mTc-maraciclatide as a diagnostic SPECT-CT agent for the “visualization of inflammation in the lungs of patients with known and suspected interstitial lung disease (ILD).”

Publication of Clinical Results: ⁹⁹ᵐTc-maraciclatide Demonstrates Excellent Potential as a Whole-Body Imaging Method for Rheumatoid Arthritis

Serac Healthcare announces that the findings from a Phase II study evaluating a novel molecular imaging agent, ^99mTc-maraciclatide, as an imaging marker for rheumatoid arthritis (RA) have been published online in Academic Radiology.

Chapter on 99mTc-maraciclatide Published in the 2025 EANM Technologists’ Guide

Serac Healthcare highlights that a chapter on ^99mTc-maraciclatide as an imaging agent for diagnosing endometriosis was published in the European Association of Nuclear Medicine’s Technologists' Guide 2025, which launched at EANM’s annual congress this week.

Molecular Imaging of Interstitial Lung Disease with Maraciclatide: PREDICT-ILD Data Presented at ERS

Serac Healthcare and the University of Exeter, today announce the first findings from a study evaluating a novel molecular imaging agent, ^99mTc-maraciclatide, as an imaging marker for interstitial lung disease evaluation. The data will be presented at the European Respiratory Society conference taking place from 27 September to 1 October in Amsterdam.

Professor Alan Perkins Awarded MBE for Services to Patient Care and Clinical Science

Serac Life Sciences, the parent company of molecular imaging businesses Serac Healthcare Ltd and Serac Imaging Systems Ltd,  announce that their Scientific Advisor, Professor Alan Perkins, has been awarded a Member of the Order of the British Empire (MBE) in the King’s Birthday Honours in recognition of his outstanding services to patient care and clinical science.

Primary Endpoint Met in the DETECT Endometriosis Imaging Study

Headline Data Presented at the World Congress on Endometriosis

Serac Healthcare Limited and the Nuffield Department of Women’s and Reproductive Health at the University of Oxford announce that the primary endpoint has been met in the “Detecting Endometriosis expressed inTegrins using teChneTium-99m” (DETECT) Phase II imaging study.